<DOC>
	<DOCNO>NCT02027961</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose safety profile MEDI4736 combination dabrafenib trametinib trametinib alone subject metastatic unresectable melanoma BRAF-mutation positive Wild Type BRAF , respectively .</brief_summary>
	<brief_title>Phase 1 Safety Tolerability MEDI4736 Combination With Dabrafenib Trametinib With Trametinib Alone</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Adults &gt; /= 18 year old Histologically confirm cutaneous melanoma either Stage IIIc ( unresectable ) Stage IV ( metastatic ) determine BRAF V600E V600K mutationpositive ( cohort A ) mutationnegative ( cohort B C ) ECOG performance status 0 1 Measurable disease radiographic physical examination Adequate organ marrow function Willingness provide consent biopsy positive BRAF WT measurable disease , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , adequate organ marrow function Prior treatment BRAF inhibitor MEK inhibitor Any prior Grade ≥ 3 immunerelated adverse event receive immunotherapy Active prior document autoimmune disease within past 2 year History current risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) History current cardiovascular risk include myocardial infarction , ≥ Class II congestive heart failure , uncontrolled arrhythmia , refractory hypertension Active , untreated CNS metastasis Women pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic Unresectable Melanoma , MEDI4736 , dafrafenib , trametinib , BRAF-mutation positive , wild-type BRAF , PD-L1 , PD-1</keyword>
</DOC>